All In Biotech

NDA 020704 · Bayer Healthcare LLC

Claritin Hives Relief Reditab

Loratadine · Oral

Last checked: Nov 19, 2026Latest source record: May 25, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Dec 23, 1996

Approved uses

3

Original approval plus efficacy supplements

Registered trials

89

27 Phase 3, 6 recruiting

FAERS reports

104,790

49,542 serious, 4,558 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 5, 2025.

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose or throat

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 19, 2003 Supplement 9 · Efficacy Letter
  • Nov 27, 2002 Supplement 8 · Efficacy ReviewLetter
  • Dec 23, 1996 Original approval · Type 3 - New Dosage Form
2 products under this application
  • CLARITIN HIVES RELIEF REDITAB · LORATADINE 10MG · TABLET, ORALLY DISINTEGRATING, ORAL · Over-the-counter
  • CLARITIN REDITABS · LORATADINE 10MG · TABLET, ORALLY DISINTEGRATING, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Loratadine" as an intervention, any sponsor and status, largest first.

All 89 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective12,371
  • fatigue6,616
  • nausea5,815
  • headache5,349
  • diarrhoea4,809
  • dyspnoea4,809
  • off label use4,642
  • dizziness4,320
  • pain4,066
  • rash3,439
  • pruritus3,375
  • cough3,094

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004966
20051,079
20061,075
2007947
20081,078
20091,328
20101,645
20112,034
20123,276
20134,246
20144,999
20157,321
20168,813
20178,781
20187,751
20197,831
20207,033
20216,297
20226,122
20235,516
20246,029
20255,967
20264,655

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 388 on PubMed

Sponsor: Bayer · Also marketed as Claritin Reditabs

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.